Rhenium Re 188 P2045 in Patients With Lung Cancer Who Have Received or Refused to Receive Prior Chemotherapy

Recruiting

Phase 1

Phase 2

Rhenium Re 188 P2045Rhenium Re 188 P2045 in Patients With Lung Cancer Who Have Received or Refused to Receive Prior Chemotherapy

Sponsor:

Andarix Pharmaceuticals

Code:

NCT00100256

Conditions

Lung Neoplasms

Carcinoma, Non-Small-Cell Lung

Carcinoma, Small Cell

Neoplasm Recurrence, Local

Eligibility Criteria

Sex: All

Age: 21+

Healthy Volunteers: Not accepted

Interventions

Rhenium (Re 188 P2045, BAY86-5284)

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-05-09. This information was provided to ClinicalTrials.gov by Andarix Pharmaceuticals on 2022-11-07.